Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
600664 Harbin Pharmaceutical Group
- 3.94
- -0.02-0.51%
Market Closed Dec 20 15:00 CST
9.92BMarket Cap16.21P/E (TTM)
3.98High3.91Low232.34KlotVolume3.96Open3.96Pre Close91.43MTurnover0.92%Turnover Ratio25.10P/E (Static)2.52BShares4.2652wk High1.90P/B9.92BFloat Cap2.4152wk Low4.36Limit Up2.52BShs Float14.17Historical High3.56Limit Down1.77%Amplitude-2.06Historical Low--Dividend TTM3.94Avg Price128.44KlotAsk--Div YieldTTM100Lot Size99.99KlotBid
Harbin Pharmaceutical Group Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 6.63%12.26B | 5.70%8.14B | 5.36%4.14B | 11.93%15.46B | 15.05%11.49B | 20.07%7.7B | 17.93%3.93B | 7.86%13.81B | 2.58%9.99B | 0.16%6.42B |
| Operating revenue | 6.63%12.26B | 5.70%8.14B | 5.36%4.14B | 11.93%15.46B | 15.05%11.49B | 20.07%7.7B | 17.93%3.93B | 7.86%13.81B | 2.58%9.99B | 0.16%6.42B |
| Other operating revenue | ---- | -5.60%28.18M | ---- | 4.82%56.21M | ---- | -32.26%29.85M | ---- | -12.17%53.63M | ---- | 114.17%44.06M |
| Total operating cost | 4.70%11.56B | 3.73%7.68B | 4.44%3.92B | 11.49%14.81B | 14.10%11.04B | 20.10%7.4B | 18.07%3.75B | 7.23%13.28B | 5.54%9.68B | 1.43%6.17B |
| Operating cost | 2.43%8.8B | -0.55%5.76B | 0.66%2.97B | 9.63%11.4B | 11.43%8.59B | 17.93%5.79B | 15.90%2.95B | 6.52%10.4B | 3.34%7.71B | -0.27%4.91B |
| Operating tax surcharges | 13.29%96.25M | 15.24%64.12M | 14.70%31.74M | -3.64%118.19M | 1.34%84.96M | -0.19%55.64M | -5.18%27.67M | 8.37%122.65M | -2.50%83.84M | -6.35%55.75M |
| Operating expense | 16.93%1.97B | 26.49%1.39B | 28.57%682.48M | 31.80%2.31B | 40.63%1.68B | 49.75%1.1B | 44.87%530.81M | 32.14%1.75B | 35.57%1.2B | 23.09%732.74M |
| Administration expense | -1.44%595.63M | 0.25%400.38M | 2.04%207.6M | 2.51%839.5M | 6.53%604.34M | 7.73%399.38M | 9.86%203.46M | -17.00%818.93M | -7.52%567.32M | -8.64%370.73M |
| Financial expense | 53.98%25.95M | 15.82%13.35M | -61.26%3.23M | -59.01%27.72M | -63.05%16.86M | -72.03%11.53M | -70.52%8.33M | -28.89%67.61M | -33.45%45.62M | -17.41%41.21M |
| -Interest expense (Financial expense) | -1.08%41.8M | -4.15%27.11M | -13.11%13.72M | -33.98%56.47M | -31.76%42.25M | -41.71%28.29M | -45.44%15.79M | -18.66%85.53M | -16.50%61.92M | -7.47%48.53M |
| -Interest Income (Financial expense) | 23.88%-26.52M | 12.00%-20.35M | -19.68%-13.51M | -63.16%-47.1M | -80.68%-34.84M | -111.81%-23.13M | -174.93%-11.29M | -84.45%-28.87M | -107.47%-19.28M | -82.84%-10.92M |
| Research and development | 20.62%81.09M | 13.49%53.41M | -23.58%25.27M | -8.45%106.02M | -13.87%67.23M | -10.08%47.06M | 34.49%33.06M | 18.49%115.81M | 26.15%78.06M | 24.72%52.34M |
| Credit Impairment Loss | -23.25%-22.75M | -99.55%-26.09M | 44.58%-4.2M | -215.01%-33.66M | 14.19%-18.46M | -510.60%-13.07M | -78.81%-7.58M | 6.91%-10.68M | 21.08%-21.51M | 78.74%-2.14M |
| Asset Impairment Loss | 6.24%-12.05M | 41.00%-8.06M | 496.12%1.94M | 48.55%-45.07M | 75.03%-12.85M | 57.24%-13.67M | 78.66%-490.16K | -61.55%-87.6M | -40.06%-51.46M | 8.95%-31.97M |
| Other net revenue | -7.19%26.7M | 48.71%14.66M | 176.37%18.87M | -93.61%10.77M | 279.08%28.77M | 181.67%9.86M | 202.30%6.83M | -25.54%168.61M | -94.21%7.59M | -108.96%-12.07M |
| Fair value change income | --0 | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- |
| Invest income | 127.78%12.79M | --12.79M | ---- | -88.88%4.48M | -85.63%5.61M | ---- | ---- | 4,650.78%40.33M | --39.07M | ---- |
| Net open hedge income | --0 | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- |
| -Including: Investment income associates | --0 | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- |
| Exchange income | --0 | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- |
| Asset deal income | -42.09%887.47K | -85.94%212.57K | 45.29%143.78K | -99.17%1.33M | -83.63%1.53M | 1.33%1.51M | 1,567.83%98.96K | -23.47%161.38M | -93.27%9.36M | -98.86%1.49M |
| Other revenue | -9.65%47.82M | 2.07%35.81M | 41.81%20.99M | 28.36%83.67M | 64.74%52.93M | 70.76%35.09M | 68.16%14.8M | -18.96%65.19M | -42.62%32.13M | -57.68%20.55M |
| Operating profit | 50.34%721.63M | 54.25%476.03M | 29.76%245.13M | -5.20%659.63M | 49.78%480M | 29.56%308.61M | 17.72%188.92M | 8.31%695.8M | -54.26%320.47M | -48.43%238.19M |
| Add:Non operating Income | 116.97%3.83M | 98.10%3.09M | -43.44%312.38K | -91.27%2.43M | -86.45%1.76M | 10.47%1.56M | -16.67%552.26K | 139.79%27.8M | 321.75%13.02M | 20.79%1.41M |
| Less:Non operating expense | 228.47%14.76M | 142.23%9.59M | -80.80%364.67K | -48.70%11.52M | -60.82%4.49M | -56.28%3.96M | -62.61%1.9M | -4.36%22.45M | -38.65%11.47M | -35.64%9.06M |
| Total profit | 48.91%710.69M | 53.34%469.53M | 30.66%245.08M | -7.22%650.54M | 48.21%477.27M | 32.82%306.2M | 20.19%187.57M | 11.20%701.15M | -52.99%322.02M | -48.66%230.54M |
| Less:Income tax cost | 26.20%162.94M | 25.35%106.37M | 15.12%54.77M | -6.68%176.32M | 4.00%129.11M | 1.17%84.86M | 3.14%47.58M | -14.39%188.94M | -20.34%124.15M | 0.58%83.88M |
| Net profit | 57.33%547.75M | 64.07%363.16M | 35.95%190.31M | -7.42%474.22M | 75.95%348.16M | 50.92%221.35M | 27.34%139.99M | 24.98%512.21M | -62.61%197.87M | -59.89%146.66M |
| Net profit from continuing operation | 57.33%547.75M | 64.07%363.16M | 35.95%190.31M | -7.42%474.22M | 75.95%348.16M | 50.92%221.35M | 27.34%139.99M | 24.98%512.21M | -62.61%197.87M | -59.89%146.66M |
| Less:Minority Profit | -31.56%39.46M | -48.83%19.77M | -23.33%13.57M | 67.77%78.95M | 39.07%57.66M | 56.81%38.64M | 86.49%17.69M | 21.41%47.06M | -2.92%41.46M | 4.73%24.64M |
| Net profit of parent company owners | 74.97%508.29M | 87.94%343.39M | 44.52%176.74M | -15.02%395.26M | 85.72%290.5M | 49.73%182.71M | 21.75%122.29M | 25.35%465.15M | -67.85%156.42M | -64.33%122.03M |
| Earning per share | ||||||||||
| Basic earning per share | 66.67%0.2 | 100.00%0.14 | 40.00%0.07 | -15.79%0.16 | 100.00%0.12 | 40.00%0.07 | 25.00%0.05 | 26.67%0.19 | -70.00%0.06 | -64.29%0.05 |
| Diluted earning per share | 66.67%0.2 | 100.00%0.14 | 40.00%0.07 | -11.11%0.16 | 100.00%0.12 | 40.00%0.07 | 25.00%0.05 | 20.00%0.18 | -68.42%0.06 | -64.29%0.05 |
| Other composite income | 133.49%399.01K | 66.95%-425.84K | -99.44%6.52K | 100.85%31.43K | 54.98%-1.19M | -20.21%-1.29M | 330.24%1.16M | 69.74%-3.71M | -27.04%-2.65M | 47.10%-1.07M |
| Other composite income of parent company owners | 133.49%399.01K | 66.95%-425.84K | -99.44%6.52K | 100.85%31.43K | 54.98%-1.19M | ---1.29M | 330.24%1.16M | 69.74%-3.71M | -27.04%-2.65M | ---- |
| Total composite income | 57.98%548.15M | 64.83%362.73M | 34.83%190.31M | -6.74%474.25M | 77.73%346.96M | 51.15%220.06M | 28.08%141.15M | 27.89%508.51M | -62.96%195.23M | -59.96%145.59M |
| Total composite income of parent company owners | 75.83%508.69M | 89.04%342.96M | 43.17%176.75M | -14.34%395.29M | 88.15%289.31M | 49.99%181.42M | 22.58%123.45M | 28.59%461.44M | -68.26%153.77M | -64.43%120.95M |
| Total composite income of minority owners | -31.56%39.46M | -48.83%19.77M | -23.33%13.57M | 67.77%78.95M | 39.07%57.66M | 56.81%38.64M | 86.49%17.69M | 21.41%47.06M | -2.92%41.46M | 4.73%24.64M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Beijing Xinghua Certified Public Accountants Firm (Special General Partnership) | -- | -- | -- | Beijing Xinghua Certified Public Accountants Firm (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
